Tag: PCSK9
ACC 2017: Positive final results from ORION-1 phase II study of inclisiran
The Medicines Company and Alnylam Pharmaceuticals have announced positive final results from the ORI...
AHA 2016: Two thirds of patients experience plaque regression with the PCSK9 inhibitor evolocumab
Amgen has announced that adding its PCSK9 inhibitor evolocumab (Repatha) to optimised statin the...
Positive top-line results from phase 3 GLAGOV imaging study of evolocumab
The Phase 3 GLAGOV (Global assessment of plaque regression with a PCSK9 antibody as measured by ...
